HER2-targeted antibody–drug conjugate carrying MMAE; binds HER2 on tumor cells, is internalized, and releases MMAE to disrupt microtubules, leading to cell-cycle arrest and apoptosis (with potential bystander effect).
HER2-targeted antibody–drug conjugate: disitamab antibody binds HER2 on tumor cells, is internalized, and a cleavable linker releases the cytotoxic payload MMAE, which disrupts microtubules, causing G2/M cell-cycle arrest and apoptosis; the released payload can diffuse to nearby cells (bystander effect).
The ADC binds HER2, is internalized, and releases the cytotoxic payload MMAE, which disrupts microtubules leading to G2/M arrest and apoptosis; released MMAE can also cause bystander killing of nearby cells.
Antibody–drug conjugate that binds a tumor-associated antigen, is internalized, and releases a topoisomerase I inhibitor payload to induce DNA damage and tumor cell death; potential bystander effect.
Nectin-4–targeted IgG1 antibody–drug conjugate; after binding and internalization, a cleavable linker releases a topoisomerase I inhibitor payload that inhibits topo I, causing DNA damage during replication and leading to cell-cycle arrest and apoptosis in antigen-expressing tumor cells, with potential bystander effect.
The ADC binds nectin-4 on target cells, is internalized, and releases a topoisomerase I inhibitor via a cleavable linker, causing DNA damage during replication leading to cell-cycle arrest and apoptosis (with potential bystander effect).
CD38-directed human IgG1 monoclonal antibody that depletes CD38+ plasma cells via ADCC, CDC, ADCP, and apoptosis and modulates the immune microenvironment.
Daratumumab is a CD38-directed human IgG1 monoclonal antibody that binds CD38 on plasma cells, inducing antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and apoptosis, while depleting CD38+ immunosuppressive cells and modulating the tumor immune microenvironment.
Anti-CD38 IgG1 binds CD38 on target cells and mediates NK-cell ADCC, complement-dependent cytotoxicity (CDC), macrophage ADCP, and can induce apoptosis upon binding/crosslinking.
CD30-directed antibody-drug conjugate delivering MMAE to malignant cells to disrupt microtubules and induce apoptosis.
CD30-directed monoclonal antibody linked via a valine-citrulline linker to the microtubule-disrupting payload monomethyl auristatin E (MMAE). After binding CD30 and internalization, lysosomal cleavage releases MMAE, which inhibits tubulin polymerization, causing G2/M arrest and apoptosis of CD30-positive malignant cells.
The ADC binds CD30, is internalized, and releases MMAE via lysosomal cleavage; MMAE inhibits tubulin polymerization, causing G2/M arrest and apoptosis of CD30+ cells.
A HER2-targeted antibody–drug conjugate in which a monoclonal antibody binds HER2 (ERBB2) on tumor cells, is internalized, and releases the cytotoxic payload monomethyl auristatin E (MMAE) to disrupt microtubules and induce apoptosis; may exert a bystander effect.
HER2-targeted antibody–drug conjugate: an anti-HER2 monoclonal antibody binds ERBB2 on tumor cells, is internalized, and a cleavable linker releases the cytotoxic payload MMAE, a microtubule inhibitor, causing mitotic arrest and apoptosis; the membrane-permeable payload may produce a bystander effect.
The ADC binds HER2 on target cells, is internalized, and releases MMAE, which inhibits microtubules, causing mitotic arrest and apoptosis; the membrane-permeable payload can also produce a bystander effect.